ArticleDiscover oncology2025
Penicilazaphilone C triggers ferroptosis in triple-negative breast cancer cells via the MDM2/p53/SLC7 A11/GPX4 pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Penicilazaphilone C (PAC) is a novel azaphilone isolated by our research team. While known for its antitumor properties, the potential of PAC to trigger ferroptosis in triple-negative breast cancer (TNBC) cells remains unexplored. This study aims to assess the ferroptotic induction capability of PAC and elucidate the underlying molecular mechanisms. Our results showed that treatment with PAC demonstrated a dose- and time-dependent inhibition of growth in MDA-MB-231 and MDA-MB-436 cells. Flow cytometry analysis and lactate dehydrogenase assay revealed various forms of cell death induced by PAC in both cell lines. Specifically, flow cytometry analyzed 7-AAD-stained dead cells, and ferroptosis markers, such as lipid peroxidation BODIPY-C11 and Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.